Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q1 2018 call → NOWe need to determine if management conveys that the company today is running on a different basis than its reported results and reputation were built on, with both halves: (1) a change of basis already real, and (2) management says the record and perception lag the change. Let's analyze the transcript. The call is about Q1 2018 results. Management discusses strong growth, particularly in sequencing consumables, microarrays, and services. They talk about NovaSeq, NextSeq, iSeq, etc. They mention partnerships with Loxo and BMS for companion diagnostics. They talk about consumer genomics, population genomics, etc. Key points: Francis deSouza says "we’re in the earliest stages of the genomics journey" and "the opportunity for Illumina and our customers in the next 20 years looks even more exciting." That's forward-looking, not a change of basis. They discuss strong consumables growth across portfolio. They mention that HiSeq consumables declined as customers transition to NovaSeq. That's a product transition, but not a fundamental change of business basis. They talk about new initiatives: partnerships with pharma for companion diagnostics, consumer genomics, etc. But are these described as already changing the company's basis? They say "we’ve a number of strategic initiatives that we believe will accelerate the adoption of sequencing and consumer and clinical applications and drive future growth." That's future. They mention that they are investing in programs to support broader adoption. They talk about the launch of iSeq, but that's a product. They mention that microarray business had a spectacular start with 48% growth, driven by consumer genomics. That's a strong quarter, but not a change of basis. They talk about the company's history: "As we celebrate our 28th birthday this month, these results highlight the vision, commitment and execution of the entire Illumina family." That's not a change. They mention that they are "proud to be part of this genomics revolution that is building momentum" and that "achievements in the first 20 years have been impressive, but the opportunity for Illumina and our customers in the next 20 years looks even more exciting." That's forward-looking. They discuss the transition to NovaSeq as a multiyear upgrade cycle. That's a product cycle. They talk about new collaborations with Loxo and BMS for companion diagnostics.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...